RU2003116133A - Solid compositions for oral administration containing non-hygroscopic salts of L-carnitine and alkanoil of L-carnitines with chlorine taurine and chlorine glycine - Google Patents

Solid compositions for oral administration containing non-hygroscopic salts of L-carnitine and alkanoil of L-carnitines with chlorine taurine and chlorine glycine

Info

Publication number
RU2003116133A
RU2003116133A RU2003116133/04A RU2003116133A RU2003116133A RU 2003116133 A RU2003116133 A RU 2003116133A RU 2003116133/04 A RU2003116133/04 A RU 2003116133/04A RU 2003116133 A RU2003116133 A RU 2003116133A RU 2003116133 A RU2003116133 A RU 2003116133A
Authority
RU
Russia
Prior art keywords
carnitine
alkanoyl
chlorine
salt
glycine
Prior art date
Application number
RU2003116133/04A
Other languages
Russian (ru)
Other versions
RU2270191C2 (en
Inventor
Мария Орнелла Тинти
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2000RM000567A external-priority patent/IT1317924B1/en
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of RU2003116133A publication Critical patent/RU2003116133A/en
Application granted granted Critical
Publication of RU2270191C2 publication Critical patent/RU2270191C2/en

Links

Claims (9)

1. Соль L-карнитина или алканоил-L-карнитина с тауринхлоридом формулы (I)1. Salt of L-carnitine or alkanoyl-L-carnitine with taurine chloride of the formula (I)
Figure 00000001
Figure 00000001
Figure 00000002
Figure 00000002
 где R представляет собой водород или низший прямой или разветвленный алканоил, содержащий от 2 до 5 углеродных атомов.where R represents hydrogen or a lower straight or branched alkanoyl containing from 2 to 5 carbon atoms. 2. Соль L-карнитина или алканоил-L-карнитина с глицинхлоридом формулы (II)2. Salt of L-carnitine or alkanoyl-L-carnitine with glycine chloride of the formula (II)
Figure 00000003
Figure 00000003
Figure 00000004
Figure 00000004
 в которой R представляет собой водород или прямой или разветвленный низший алканоил, содержащий от 2 до 5 углеродных атомов.in which R represents hydrogen or a straight or branched lower alkanoyl containing from 2 to 5 carbon atoms. 3. Соль по п.1 или 2, в которой R выбирают из группы, состоящей из ацетила, пропионила, бутирила, валерила или изовалерила.3. The salt according to claim 1 or 2, in which R is selected from the group consisting of acetyl, propionyl, butyryl, valeryl or isovalery. 4. Композиция, содержащая в качестве активного ингредиента соединение общей формулы (I) или (II) по пп.1, 2 или 3.4. A composition containing, as an active ingredient, a compound of the general formula (I) or (II) according to claims 1, 2 or 3. 5. Композиция по п.4, дополнительно содержащая одно или более веществ, выбранных из фармакологически приемлемых наполнителей и активных ингредиентов.5. The composition according to claim 4, additionally containing one or more substances selected from pharmacologically acceptable excipients and active ingredients. 6. Композиция по п.4 или 5 в виде таблеток, жевательных таблеток, капсул, гранул или порошков.6. The composition according to claim 4 or 5 in the form of tablets, chewable tablets, capsules, granules or powders. 7. Композиция по пп.4-6, в виде стандартной дозированной формы, включающая, в качестве активного ингредиента, соль L-карнитина или алканоил-L-карнитина формул (I) или (II), содержащая 50-2000, предпочтительно 100-1000 мг L-карнитина или алканоил-L-карнитина в расчете на внутреннюю соль.7. The composition according to claims 4-6, in unit dosage form, comprising, as an active ingredient, an L-carnitine or alkanoyl-L-carnitine salt of the formulas (I) or (II), containing 50-2000, preferably 100- 1000 mg of L-carnitine or alkanoyl-L-carnitine calculated on the internal salt. 8. Композиция по пп.4-7, предназначенная для употребления человеком в качестве пищевой добавки или диетического продукта.8. The composition according to claims 4-7, intended for human consumption as a dietary supplement or dietary product. 9. Композиция по п.8, предназначенная для ветеринарного применения в качестве добавки в корм животных.9. The composition of claim 8, intended for veterinary use as an additive in animal feed.
RU2003116133/04A 2000-10-31 2001-09-28 Solid compositions for oral using comprising nonhygroscopic l-carnitine and alkanoyl l-carnitine salt with taurine chloride RU2270191C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2000A000567 2000-10-31
IT2000RM000567A IT1317924B1 (en) 2000-10-31 2000-10-31 SOLID COMPOSITIONS FOR ORAL ADMINISTRATION INCLUDING HYGROSCOPIC SALINONS OF L-CARNITINE AND ALCANOYL L-CARNITINE WITH

Publications (2)

Publication Number Publication Date
RU2003116133A true RU2003116133A (en) 2004-12-10
RU2270191C2 RU2270191C2 (en) 2006-02-20

Family

ID=11454973

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003116133/04A RU2270191C2 (en) 2000-10-31 2001-09-28 Solid compositions for oral using comprising nonhygroscopic l-carnitine and alkanoyl l-carnitine salt with taurine chloride

Country Status (25)

Country Link
US (1) US7858820B2 (en)
EP (1) EP1330428B1 (en)
JP (1) JP4181406B2 (en)
KR (1) KR100764155B1 (en)
CN (1) CN1219748C (en)
AT (1) ATE312810T1 (en)
AU (2) AU2001295893B2 (en)
BR (1) BRPI0115019B1 (en)
CA (1) CA2427482C (en)
CY (1) CY1106062T1 (en)
CZ (1) CZ302802B6 (en)
DE (1) DE60115944T2 (en)
DK (1) DK1330428T3 (en)
ES (1) ES2253430T3 (en)
HK (1) HK1061230A1 (en)
HU (1) HU229989B1 (en)
IT (1) IT1317924B1 (en)
MX (1) MXPA03003799A (en)
NZ (1) NZ525333A (en)
PL (1) PL205801B1 (en)
RU (1) RU2270191C2 (en)
SI (1) SI1330428T1 (en)
SK (1) SK287133B6 (en)
WO (1) WO2002036543A1 (en)
ZA (1) ZA200303328B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005031705A1 (en) * 2005-07-05 2007-01-18 Henkel Kgaa Composition containing L-carnitine or L-carnitine derivatives and at least one further substance selected from taurine and its derivatives and at least one active substance obtainable from plants of the genus Echinacea
KR101007927B1 (en) 2008-12-24 2011-01-14 주식회사 셀트리온제약 Sibutramine-L-carnitine disulfonate, process for preparing the same, and pharmaceutical composition including the same
JP5451558B2 (en) * 2010-08-27 2014-03-26 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Gels useful for the delivery of cosmetic active ingredients
CN104276986B (en) * 2013-07-12 2016-07-06 辽宁科硕营养科技有限公司 The preparation method of L-carnitine taurate
JP6473352B2 (en) * 2015-03-10 2019-02-20 利幸 糸井 Drug for ischemic disease
CN107325013B (en) * 2016-04-28 2019-04-12 辽宁科硕营养科技股份有限公司 A method of synthesis glycine propionyl levo-carnitine hydrochloride

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150688B1 (en) * 1983-12-28 1987-04-22 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
CA2030310A1 (en) * 1989-12-22 1991-06-23 Ronald E. Macleay Derivatives of n-hals-substituted amic acid hydrazides
IT1291126B1 (en) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION INCLUDING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND L-CARNITINE ALCANOYLS
IT1306147B1 (en) 1999-05-28 2001-05-30 Biosalts Srl DERIVATIVES OF ACTIVE INGREDIENTS FOR THERAPEUTIC AND / OR NUTRITIONAL ACTIVITIES AND COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING SUCH

Similar Documents

Publication Publication Date Title
ES2313616T3 (en) USE OF SALTS, ADDITION REACTION COMPOUNDS AND COMPLEX COMPOUNDS OF GUANIDINOACETIC ACID.
JP2003526622A5 (en)
JPH0717501B2 (en) Pharmaceutical products that provide enhanced analgesia
AU627041B2 (en) Improved nutritional formulation for the treatment of renal disease
JP2009242413A (en) Medicine based on amino acid
US4315028A (en) Method of treatment of rheumatoid arthritis
US5952379A (en) Stable, non-hygroscopic salts of L(-)carnitine and alkanoyl L(-)carnitines, a process for their preparation and solid, orally administrable compositions containing such salts
US4487780A (en) Method of treatment of rheumatoid arthritis
RU2006120946A (en) COMPOSITION OF PREGABALIN
RU2003116133A (en) Solid compositions for oral administration containing non-hygroscopic salts of L-carnitine and alkanoil of L-carnitines with chlorine taurine and chlorine glycine
CN101209975B (en) Levulorotation carnitine calcium fumarate and its preparing method and use
IE843148L (en) Compositions comprising thiadiazines
JPS62270522A (en) Nutrient enhancer for treating uremia
CA2427482A1 (en) Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride
WO2007142707A1 (en) Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals
JP2004513107A5 (en)
HRP20120177T1 (en) Carnitine-containing peritoneal dialysis solution having improved biocompatibility
CA2534910A1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
US3708574A (en) Pharmaceutical compositions providing potassium chloride in aqueous solution
NZ500538A (en) Solid compositions suitable for oral administration comprising L-carnitine and alkanoyl-L-carnitine magnesium tartrate
JP2008532601A5 (en)
US4681756A (en) Prevention of N-nitroso compound formation in vivo
AU2009356961B2 (en) Effervescent L-carnitine-based composition
JP2006511531A5 (en)
JP2002519403A5 (en)